Valens GroWorks Closes First Tranche of Offering
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
UPDATE: on November 29th, 2017, Valens Closed the Second Tranche of Offering. For more information please visit: Valens GroWorks Closes Second Tranche of Offering
Valens GroWorks Corp. (CSE: VGW) (the “Company” or “Valens”), a biotechnology company specializing in the production, research, development and commercialization of novel, cannabinoid-based products and drug therapies, is pleased to announce the closing of its first tranche of offering. This is 207,500 units (the “Units”) for proceeds of $207,500, and it’s the first tranche of its non-brokered private placement to raise up to $500,000 at a price of $1.00 per Unit (the “Offering”) as announced on October 25, 2017.
An insider participated for 110,000 Units representing $110,000 in cash. The Company intends to use the proceeds of the Offering for ongoing plant expansion costs including additional growing and oil extraction capacity at existing facilities, and for general corporate purposes.
Closing of the first tranche of Offering is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, including the CSE. All securities issued pursuant to this private placement are subject to a hold period expiring four months and one day from the date of issuance.
About Valens GroWorks Corp.
Valens GroWorks Corp. is a biotechnology company with an aggressive buildout strategy. The Company seeks to capture a broad spectrum of medical cannabis users, and adult recreational users once legalized, as well as clinical trial and R&D clients, in pursuit of its ambitious “plants to premium products” objectives.
The Company operates a 17,000 square foot facility located on two acres in Kelowna, in the heart of British Columbia’s Okanagan Valley. Wholly owned subsidiary Supra THC Services Inc. (“Supra”), in collaboration with Thermo Fisher Scientific, a world leader in Health Science services, is developing a “Centre of Excellence in Plant Based Medicine Analytics” to provide analytical services and directed research and development, including clinical trials. Supra and the Company’s subsidiary Valens AgriTech Ltd. (“Valens AgriTech”), a Health Canada Licensed Dealer, recently announced a $330,000 MITACS funded research grant and collaboration with UBC Okanagan and Thompson Rivers University to explore potential cannabis bio-products including pharmaceuticals, nutritional products, and industrial fibre.
For more information, visit thevalenscompany.com.au
On behalf of the Board of Directors, VALENS GROWORKS CORP.
(signed) “Rob van Santen”
Chief Financial Officer
For further information, please contact:
Notice Regarding Forward Looking Statements
This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed”, “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections
contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable law.
The CSE or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.